Portable device that detects Sepsis in minutes

Europe: Sepsis is associated with the body's inflammatory response to a bacterial infection and progresses extremely rapidly. It is one of the ten leading causes of death worldwide claiming one life every four seconds.

Sepsis progresses very fast so much so every hour lost in diagnosing it increases the mortality rate by nearly 8%. Time is critical with sepsis, but the tests currently used in hospitals can take up to 72 hours to provide a diagnosis. Many scientists are working on developing technology for faster diagnosis of Sepsis.

Researchers at the Laboratory of Bionanophotonic Systems (BIOS) at EPFL's School of Engineering have developed an optical biosensor that slashes the sepsis diagnosis time from several days to just a few minutes. Their novel approach draws on recent developments in nanotechnology and on light effects at the A portablenanoscale to create a highly portable, easy-to-use device that can rapidly detect sepsis biomarkers in a patient's bloodstream. And their device takes just a few minutes to deliver a result, like a pregnancy test.

The findings of the research have been published in the journal Small.

The highly sensitive and portable optical biosensor which stands to accelerate the diagnosis of sepsis could be used by ambulances and hospitals to improve the triage process and save lives.

Because the biosensor uses a unique plasmonics technology, it can be built from small, inexpensive components, yet it can achieve accuracy on par with gold-standard laboratory methods. The device can screen a large panel of biomarkers and be adapted for the rapid diagnosis of a number of diseases. It was installed at Vall d'Hebron University Hospital in Spain and used in blind tests to examine patient samples from the hospital's sepsis bank. The researchers' technology is patent-pending, and their findings were recently published in Small.

The device employs an optical metasurface - in this case, a thin gold sheet containing arrays of billions of nanoholes. The metasurface concentrates light around the nanoholes so as to allow for exceptionally precise biomarker detection. With this type of metasurface, the researchers can detect sepsis biomarkers in a blood sample with nothing more than a simple LED and a standard CMOS camera.

The researchers begin by adding a solution of special nanoparticles to the sample that are designed to capture the biomarkers. They then distribute this mixture on the metasurface. "Any nanoparticles that contain captured biomarkers are trapped quickly by antibodies on the nanoholes," says Alexander Belushkin, the lead author of the study. When an LED is applied, those nanoparticles partially obstruct the light passing through the perforated metasurface. "These nano-scale interactions are imaged by the CMOS camera and digitally counted in real-time at high precision," says Filiz Yesilkoy, the study's co-author. The generated images are used to rapidly determine whether disease biomarkers are present in a sample and, if so, in what concentration. They used the new device to measure the blood serum levels of two important sepsis relevant biomarkers, procalcitonin, and C-reactive protein. Doctors can use this information to accelerate the triage of sepsis patients, ultimately saving lives.

"We believe our low-cost, compact biosensor would be a valuable piece of equipment in ambulances and certain hospital wards," says Hatice Altug, the head of BIOS. Scientists already have possible applications in mind. "There is an urgent need for such promising biosensors so that doctors can diagnosis sepsis accurately and quickly, thereby keeping patient mortality to a minimum," say Anna Fàbrega and Juan José González, lead doctors at Vall d'Hebron University Hospital.

For more details click on the link:

Alexander Belushkin, Filiz Yesilkoy, Juan Jose González‐López, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Anna Fàbrega, Hatice Altug. Rapid and Digital Detection of Inflammatory Biomarkers Enabled by a Novel Portable Nanoplasmonic Imager. Small, 2019; 16 (3): 1906108 DOI: 10.1002/smll.201906108